The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes.
 
Hima Bindu Musunuru
No Relationships to Disclose
 
Andrea Deabreu
No Relationships to Disclose
 
Melanie Davidson
No Relationships to Disclose
 
Ananth Ravi
No Relationships to Disclose
 
Joelle Antoine Helou
No Relationships to Disclose
 
Ling Ho
No Relationships to Disclose
 
Patrick Cheung
No Relationships to Disclose
 
Danny Vesprini
No Relationships to Disclose
 
Stanley K. Liu
No Relationships to Disclose
 
William Chu
No Relationships to Disclose
 
Renee Korol
No Relationships to Disclose
 
Hans T. Chung
Honoraria - AstraZeneca; Bayer; Sanofi
Consulting or Advisory Role - Elekta
 
Alexandre Mamedov
No Relationships to Disclose
 
Liying Zhang
No Relationships to Disclose
 
Andrew Loblaw
Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb (I); Ferring; GlaxoSmithKline (I); Janssen Oncology; Merck (I); Novartis (I); Roche (I)
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Atlas Global Healthcare; Bayer; Bristol-Myers Squibb (I); Ferring; GlaxoSmithKline (I); Janssen Oncology; Merck (I); Novartis (I); Roche (I)
Patents, Royalties, Other Intellectual Property - Prostate immobilization device (GU-Lok)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen Oncology
Other Relationship - TSRCC Radiation Oncology Associates